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ABSTRACT
Previous studies have shown that a major block to HIV-1 replication in commonmarmosets operates at the level of viral entry
and that this block can be overcome by adaptation of the virus in tissue-cultured cells. However, our current studies indicate that
HIV-1 encounters additional postentry blocks in commonmarmoset peripheral bloodmononuclear cells. Here, we show that
the commonmarmoset APOBEC3G (A3G) and BST2 proteins block HIV-1 in cell cultures. Using a directed-evolutionmethod
that takes advantage of the natural ability of HIV-1 to mutate during replication, we have been able to overcome these blocks in
tissue-cultured cells. In the adapted viruses, specific changes were observed in gag, vif, env, and nef. The contribution of these
changes to virus replication in the presence of the A3G and BST2 restriction factors was studied. We found that certain amino
acid changes in Vif and Env that arise during adaptation to marmoset A3G and BST2 allow the virus to replicate in the presence
of these restriction factors. The changes in Vif reduce expression levels and encapsidation of marmoset APOBEC3G, while the
changes in Env increase viral fitness and discretely favor cell-to-cell transmission of the virus, allowing viral escape from these
restriction factors.
IMPORTANCE
HIV-1 can infect only humans and chimpanzees. The main reason for this narrow tropism is the presence in many species of
dominant-acting factors, known as restriction factors, that block viral replication in a species-specific way. We have been explor-
ing the blocks to HIV-1 in commonmarmosets, with the ultimate goal of developing a new animal model of HIV-1 infection in
these monkeys. In this study, we observed that commonmarmoset APOBEC3G and BST2, two known restriction factors, are
able to block HIV-1 in cell cultures. We have adapted HIV-1 to replicate in the presence of these restriction factors and have
characterized the mechanisms of escape. These studies can help in the development of a novel animal model for in vivo infection
of marmosets with HIV-1-like viruses.
The main cause of AIDS is chronic infection by human immu-nodeficiency virus type 1 (HIV-1). Without treatment, HIV-1
infection results in a progressive depletion of CD4 T cells that
leads to severe immunodeficiency, characterized by opportunistic
infections and certain types of cancer that are the leading causes of
death in HIV-1-positive patients.
The presence of several barriers to HIV-1 replication in cells of
many species narrows the viral tropism to humans and chimpan-
zees. The limited species tropism of HIV-1 is due to two types of
host factors: (i) factors that are required for HIV-1 replication but
that exhibit species-specific changes that do not allow efficient use
by HIV-1 and (ii) dominant-acting factors that block replication
in many species. The latter, also known as restriction factors, are
part of so-called intrinsic antiviral immunity. Altogether, intracel-
lular restriction factors can act as powerful barriers to viral repli-
cation. However, viruses have developed mechanisms that can
antagonize restriction factors in an equally successful way. These
viral countermeasures are often proteins encoded by accessory
genes that are not needed for viral replication in the absence of
restriction factors. The main restriction factors that block HIV-1
and other lentivirus infections at different stages of the viral life
cycle are TRIM5 (1), APOBEC3G (A3G) (2), BST2 (3, 4),
SAMHD1 (5, 6), and the recently discovered Mx2 (7–9).
BST2, also known as tetherin, CD317, or HM1.24, tethers viral
particles to the plasmamembrane of the cell, blocking their release
(3, 4). BST2 is able to block the release of a broad range of envel-
oped viruses (10, 11). To escape from the action of BST2, viruses
have developed a variety of strategies. In HIV-1, the accessory
proteinVpu suppresses the activity of humanBST2; inHIV-2, Env
is the protein responsible for counteracting the activity of BST2,
whereas Nef overcomes the restriction imposed by BST2 in most
simian immunodeficiency viruses (SIVs) (12–16). A3G and
APOBEC3F (A3F) are cellular cytidine deaminases that can be
incorporated into virions in a species-specific way, blocking virus
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replication by various mechanisms. These mechanisms include
hypermutation of the viral genome during reverse transcription,
which leads to degradation of the replication intermediates or
generation of noninfectious virions, inhibition of elongation of
HIV-1 DNA by reverse transcriptase (RT), and reduction of the
efficiency of plus-strand DNA transfer and inhibition of integra-
tion (17–22). The viral infectivity factor (Vif) can inhibit incorpo-
ration of the A3G/A3F proteins in a species-specific manner by
promoting their degradation (23–25).
Due to the limited tropism of HIV-1, the development of an
animal model of HIV-1 infection has been challenging. The in-
creased knowledge and understanding of the host restriction fac-
tors that block replication of HIV-1 in the last few years has al-
lowed the construction of some macaque-tropic HIV-1 variants
that contain about 90%HIV-1 sequences and 10% SIV sequences
(26, 27) and that are able to replicate efficiently in macaque pe-
ripheral blood lymphocytes (PBLs). Some of these adapted viruses
have been shown to causeAIDS in pigtailmacaques that have been
treated with anti-CD8 antibodies to transiently deplete CD8 T
cells (28).
To date, lentiviruses able to infect New World monkeys have
not been described. Our knowledge of the host restriction factors
that block replication of lentiviruses in New World monkeys is
fragmentary. However, some of these monkeys, like common
marmosets, have been frequently used in animal models in other
fields and are an attractive prospect for the development of a new
animalmodel of HIV-1 infection. Previous studies have suggested
that one major blockade to HIV-1 infection in New World mon-
keys occurs at the level of viral entry, because HIV-1 envelope
glycoproteins cannot effectively bind the CD4 and CCR5 recep-
tors of common marmosets (29). Using a directed-evolution
method that takes advantage of the natural ability of the virus to
mutate during replication, we were able to generate HIV-1 vari-
ants able to replicate in cells expressing the common marmoset
receptors CD4 and CXCR4 (30). The adapted viruses, however,
were unable to replicate in common marmoset PBLs, suggesting
the presence of additional postentry blocks. In this study, we ob-
served that common marmoset A3G (marA3G) and BST2
(marBST2) proteins block HIV-1 in cell cultures, and we
adapted HIV-1 to replicate in the presence of these restriction
factors. The basis for the observed escape of the adapted viruses
was studied.
MATERIALS AND METHODS
Cell lines and reagents. 293T and Cf2Th cells were obtained from the
American Type Culture Collection and maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10% fetal bovine se-
rum (DMEM-10). The 174CEM cells were obtained from the NIH
AIDS Research and Reference Reagent Program (catalog number 272)
from Peter Cresswell (31) and maintained in RPMI 1640 supplemented
with 10% fetal bovine serum (RPMI-10).
Cf2Th cell lines stably expressing marmoset or human CD4 and
CXCR4have been described previously (30). Cf2Th cells stably expressing
marmoset A3G or BST2 and marmoset CD4 and CXCR4 receptors were
prepared by transfecting the Cf2Th-CD4-CXCR4 cell lines with a
pcDNA3.1() plasmid expressing marmoset A3G or BST2 with a C-ter-
minal or N-terminal hemagglutinin (HA) tag, respectively. The trans-
fected cells were selected with antibiotic to obtain stable cell lines express-
ing the proteins. Then, single clones expressing marmoset CD4, CXCR4,
and A3G or BST2 were obtained by limited dilution. Alignments of the
marmoset A3G and BST2 proteins with ortholog proteins of other species
are shown in Fig. S1 and S2, respectively, in the supplemental material.
The following reagents were obtained through the NIH AIDS Re-
search and Reference Reagent Program, Division of AIDS (DAIDS),
NIAID, NIH: HIV-1 SF2 p24 antiserum (catalog number 4250) from
DAIDS, NIAID, produced by BioMolecular Technologies; anti-human
BST2 (catalog number 11721) from Klaus Strebel and Amy Andrew (32);
pcDNA-HVif (catalog number 10077) and pcDNA-Vphu (catalog num-
ber 10076), both from Stephan Bour and Klaus Strebel (33); pNL-U35
(catalog number 968) from Klaus Strebel (34); and Nevirapine (catalog
number 4666).
Virus replication.Replication-competentHIV-1 variants were gener-
ated by transfecting 20 g of the pNL4-KBCJ1.2 plasmid, which contains
an infectious HIV-1 NL4.3 provirus, with the KB9 Env sequence contain-
ing the changes E151K, E172K, and A561T, which allow the use of mar-
moset CD4 and CXCR4 (30), into 2  106 293T cells using the calcium
phosphate transfection method as previously reported (30).
For the replication kinetics assays, cells were infected with 30,000 RT
units (cpm) of HIV-1 NL4-KBCJ1.2 variants for 14 h and then washed
once with phosphate-buffered saline (PBS). Every 3 or 4 days, the cell
supernatants were removed and used for RT assays. The cells were
trypsinized, diluted 1/5 in fresh medium, and replated.
Analysis of the sequences of adapted viruses. The genomes of the
adapted viruses were amplified by PCR from genomic DNA isolated from
infected cells with the QIAamp DNA blood minikit (Qiagen). Five PCR
fragments containing long terminal repeat (LTR)-gag, pol, Vif-Vpu, Env,
or Nef-LTR sequences were generated by PCR with PfuUltra High-Fidel-
ity DNA polymerase (Stratagene) and overlapping primers designed to
cover the entire genome. These fragments were either cloned into the
pCR4blunt-TOPO plasmid (Invitrogen) and sequenced or directly se-
quenced to obtain the consensus sequence of the adapted viruses.
Site-directed mutagenesis. DNA sequences of consensus changes in
matrix, Vif, Env, and Nef that were associated with viral adaptation to
marA3G ormarBST2 were introduced by site-directedmutagenesis using
the QuikChange II XL site-directed mutagenesis protocol (Stratagene)
into the pNL4-KBCJ1.2 plasmid; the pCMVP1envpA plasmid con-
taining the gag, pol, and vif regions of NL4-3 HIV-1; or the pSVIII-
KBCJ1.2 plasmid expressing the full-length HIV-1(KBCJ1.2) envelope
glycoprotein. The presence of the desired mutations was verified by auto-
mated DNA sequencing.
Single-cycle infectivity assay.The efficiency of a single cycle of HIV-1
infection wasmeasured by using recombinant reporter viruses expressing
firefly luciferase and pseudotyped with the vesicular stomatitis virus G
glycoprotein (VSV-G) or HIV-1 Env. Recombinant luciferase-expressing
HIV-1 variants (35) were generated by transfecting 293T cells using the cal-
cium phosphate transfection method with 4 g of the pCMVP1envpA
packaging plasmid, 4 g of an HIV-1-derived vector plasmid that ex-
presses the firefly luciferase, and 2 g of the pSVIII-Env plasmid express-
ing HIV-1 Env or 1 g of the pHCMV-G plasmid expressing the VSV
envelope glycoprotein G and 1g of a Rev-expressing plasmid. In certain
experiments, viruses were produced in the presence of A3G or BST2,
including different amounts of pcDNA3.1() plasmid expressing these
proteins in the transfection mixture. Forty-eight hours after transfection,
supernatants containing reporter viruses were harvested and cleared by
low-speed centrifugation. The amounts of virus in the supernatants were
quantified by measuring the RT activity.
Target cells were seeded at a density of 6,000 cells/well in 96-well lu-
minometer-compatible tissue culture plates. Twenty-four hours later, the
medium was changed and different amounts of viruses were added to the
cells. Forty-eight hours later, the medium was removed and cells were
lysed with 30 l of passive lysis buffer (Promega). Luciferase activity was
measured using a Berthold Centro LB 960 microplate luminometer or a
BMG Labtech Fluostar Optima microplate reader.
Encapsidation of APOBEC3G. Recombinant viruses with different
Vif variants were generated in the presence or absence of A3G. For this
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purpose, 293T cells were seeded in 6-well plates at a density of 3 105 per
well and cotransfected using the calcium phosphate transfection method
with the pHCMV-G plasmid expressing VSV envelope glycoprotein G; a
Rev-expressing plasmid; the pCMVP1envpA packaging plasmid con-
taining the different Vif variants; a plasmid expressing the reporter firefly
luciferase gene; and a pcDNA3.1 vector expressing marA3G or huA3G,
both containing a C-terminal HA tag for easy detection by Western blot-
ting (WB); or an empty pcDNA3.1 vector. Forty-eight hours after trans-
fection, supernatants containing viruses were harvested, cleared by low-
speed centrifugation, and filtered with a 0.45-mpolyethersulfone (PES)
filter. The viruses were pelleted though a 20% sucrose cushion by centrif-
ugation at 4°C in a fixed-angle rotor for 1 h at 30,000 g. The viruses were
analyzed by SDS-PAGE and WB probing with anti-p24 and anti-HA
(clone 3F10; Roche) antibodies. The blots were visualized with an Im-
ageQuant LAS 4000 mini Imager, and the amounts of A3G and p24 were
quantified using Quantity One software (Bio-Rad).
Coexpression of APOBEC3G and Vif mutants. 293T cell were
cotransfected with a pcDNA3.1 vector expressing marA3G, human A3G
(huA3G), African greenmonkeyA3G (agmA3G), or rhesusmacaqueA3G
(rhA3G) containing a C-terminal HA tag or an empty pcDNA3.1 vector
and the pcDNA-HVif plasmid, which contains a partially codon-opti-
mized Vif. The cells were incubated for 24 h in the presence or absence of
10MMG132 and thenwere harvested and lysedwith 40l of lysis buffer
(1% NP-40 in PBS plus 2 mM EDTA, 1 mM benzamidine, and 2 mM
phenylmethylsulfonyl fluoride [PMSF] as protease inhibitors). The cell
lysates were analyzed by SDS-PAGE and WB probing with an anti-HA
antibody. The blotswere stripped and reprobedwith an anti-Vif antibody;
then, the membranes were stripped again and probed with an anti--
tubulin antibody. The blots were visualized with an ImageQuant LAS
4000 mini Imager, and the amounts of A3G, Vif, and tubulin were quan-
tified using Quantity One software (Bio-Rad).
Cell-to-cell transmission assay. 293T cells (producer or donor cells)
were plated in 12-well plates at a final concentration of 2  105/ml and
cotransfected with a pcDNA3.1 plasmid, empty or expressing marBST2;
the pSVIIIenv plasmid, which contains the different Env variants; a plas-
mid expressing green fluorescent protein (pHIV-1-GFP); and the
pCMVP1envpA packaging plasmid. One day later, 174CEM cells
(target cells) were labeled with CellTrace Far Red DDAO-SE dye (Invit-
rogen) at a concentration of 1 Mdiluted in PBS for 15 min at 37°C. The
labeled target cells were added to donor cells at a final concentration of
106/ml and cocultured for 48 h. The reverse transcriptase inhibitor nevi-
rapine (NVP) was added at a concentration of 20 M to a control sample
when the coculture was started and maintained during the assay. After 48
h of coculture, cells were harvested, washed twice with PBS, and fixedwith
1% formaldehyde in PBS. The cells were analyzed in a FACSCanto A flow
cytometer, and the percentage of double-positive cells was calculated.
Particle release assay. 293T cells were cotransfected with the pNL4-
KBCJ1.2 plasmid containing the full-length HIV-1 proviral genome with
wild-type (WT) ormutant Env or the plasmid pNLU35, which contains an
HIV-1 proviral genome with the vpu gene deleted, and either an empty
pcDNA3.1 vector or different amounts of a pcDNA3.1 vector expressing
marBST2 or huBST2 with an N-terminal HA tag. In some cases, the cells
were also cotransfected with a plasmid (pcDNA-Vphu) expressing the
Vpu protein or a plasmid expressing the Nef protein from SIVmac. Twen-
ty-four hours posttransfection, the cells were harvested and lysed with
lysis buffer containing protease inhibitors. Cell culture supernatants
containing the released viruses were filtered with a 0.45-m PES filter
and pelleted through a 20% sucrose-PBS cushion by centrifugation at
30,000  g for 1 h. Pelleted viruses and cell lysates were analyzed by
WB with an anti-p24 polyclonal antibody and a monoclonal anti-HA
antibody. The blots were visualized with an ImageQuant LAS 4000
mini Imager, and the percentage of particle release was calculated as
the ratio between the p24 in the cell culture supernatants and the total
p24 (cells plus virions).
Statistics.All experiments were done at least twice (inmost cases three
or more times). The means and standard deviations were calculated with
the Excel program.When appropriate, two-tailedP values were calculated
using the Sigma Plot program’s Student t test.
Nonhuman primate blood samples and ethics statement. Blood
samples from commonmarmosets and rhesusmacaques were used in this
study to isolate mRNA needed for cloning A3G and BST2. The animals
were housed at the New England Primate Research Center and were cared
for according to the standards of the Association for Assessment and
Accreditation of Laboratory Animal Care and the Harvard Medical
School Animal Care and Use Committee.
Collection of nonhuman primate blood samples for this study was
approved by the Harvard Medical Area (HMA) Standing Committee on
Animals (protocol number 04789) and conducted in accordance with the
Guide for the Care and Use of Laboratory Animals by experienced veter-
inarians at the New England Primate Research Center.
The HMA Standing Committee on Animals has an approved animal
welfare assurance on file with the Office for Laboratory Animal Welfare.
The assurance number on file is A3431-01.
For this study, only nonsurgical collection of blood was needed. No
other procedures were carried out on the animals for the study. For phle-
botomy, the animals were sedated with ketamine HCl (10 to 50 mg/kg of
bodyweight intramuscularly [i.m.]) or with telazol (4 to 10mg/kg i.m.) to
reduce pain and discomfort. The phlebotomy site was prepped with alco-
hol. Blood samples were obtained from a peripheral vein. The amounts of
blood collected from any animal as a single sample did not exceed 10% of
the circulating blood volume every 2 weeks.
The common marmosets utilized in this study were socially housed.
The rhesus macaques were socially housed unless they were being condi-
tioned for other studies or were scheduled for return to the breeding
colony. Compensatory enrichment was provided to animals that were not
socially housed. The enrichment provided include manipulable devices,
foraging opportunities, food items, structural and environmental en-
hancements, and positive human interaction. Enrichment devices were
rotated on a weekly basis and included toys, mirrors, radios, TVs/VCRs,
foraging boards, and a variety of complex foraging devices.
RESULTS
Common marmoset APOBEC3G and BST2 block HIV-1 infec-
tion. We were intrigued by the lack of infectivity in marmoset
PBLs of the HIV-1 variants adapted to replicate in the presence of
marmoset CD4 and CXCR4. We assessed the ability of marA3G
and marBST2 proteins to block HIV-1.
Previous studies had shown that marA3G was able to block
HIV-1 (36). To assess the anti-HIV-1 activity of marA3G, we pre-
pared single-round luciferase reporter viruses in 293T cells in the
presence or absence of marA3G and tested their infectivity in
Cf2Th target cells. Using this system, we observed that the infec-
tivity of viruses prepared in the presence of marA3G was about
10-fold lower than that of the viruses prepared in the absence of
A3G (Fig. 1A), indicating that marA3G has an inhibitory effect on
the infectivity of HIV-1, in agreement with previous work (36).
Several studies have shown that certain regions in theN-termi-
nal part of Vif are important for A3G and A3F binding (37–40).
We selected a few residues in these regions that we observed to be
conserved within the same viral species but not between different
species of primate lentiviruses and generated a small library of
single and double Vif mutants containing specific changes at res-
idues 34, 36, and 41. In this library, we also included a triple mu-
tant of Vif containing the amino acid changes D14S, R15E, and
R17Q (SEMQ); this mutant was previously shown to be able to
interact with rhA3G and to productively replicate in human cells
that express rhA3G (41). To test the ability of these Vif mutants to
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counteract marA3G, we prepared viruses containing these Vif
changes in the presence or absence of marA3G and tested their
infectivity in target cells. Viruses containing the SEMQVifmutant
exhibited an approximately 2-fold increase in infectivity com-
pared to theWT virus when prepared in the presence of marA3G,
indicative of a partial escape from the restriction factor (Fig. 1A).
All the other Vifmutants tested did not show a significant increase
in their infectivity in the presence of marA3G (data not shown).
To test the ability ofmarBST2 to block the release of HIV-1, we
coexpressed BST2, which contained an N-terminal HA tag, with
HIV-1 NL4.3 lacking Vpu (Vpu) in 293T cells. As previously
reported (3, 4), in the absence of Vpu, huBST2 drastically reduced
the amount of viral particles released into the medium, and the
addition of HIV-1 Vpu, but not SIVmac Nef, was able to recover
the particle release (Fig. 1B). Similarly, marBST2 also decreased
the amount of viral particles released; however, the addition of
HIV-1 Vpu or SIVmac Nef was not able to counteract the effect of
marBST2 or induce degradation of marBST2 (Fig. 1B). Of note,
the effect of marBST2 on HIV-1 particle release was not as strong
as the block imposed by huBST2. This might be related to lower
levels of expression or anti-HIV-1 activity of marBST2 compared
with those of huBST2.
To evaluate if the two marmoset restriction factors efficiently
inhibited HIV-1 replication, we infected Cf2Th cell lines express-
ing marA3G or marBST2, as well as commonmarmoset CD4 and
CXCR4, with the NL4-KBCJ1.2 virus. TheNL4-KBCJ1.2 virus is a
FIG 1 Restriction of HIV-1 by common marmoset APOBEC3G and BST2. (A) Cf2Th cells were infected with VSV-G-pseudotyped HIV-1 luciferase reporter
viruses prepared in the absence or presence ofmarA3G.The infectivity of the viruseswas determined bymeasuring the relative luciferase activity in the target cells.
RLU, relative luciferase units. Similar results were obtained in three independent experiments. The chart shows the results of one representative experiment. (B)
293T cells were cotransfected with a NL4-3Vpu proviral plasmid and different amounts of plasmids expressingmarmoset or human BST2. In some cases, cells
were also cotransfected with plasmids expressing HIV-1 Vpu or SIVmac Nef. Twenty-four hours later, the mediumwas collected and the viruses were pelleted by
centrifugation in a 20% sucrose cushion. The cell lysates and viruses were analyzed by immunoblot probing with an anti-p24 antibody. The relative particle
releasewas calculated by dividing the amount of p24 in the supernatant by the total p24 (cells plus supernatant). Themembraneswere stripped and reprobedwith
an anti-HAantibody (to detect BST2HA); then, themembraneswere stripped again andprobedwith an anti-tubulin (tubulin) antibody as a loading control. The
WBs of one representative experiment out of four are shown. (C) Cf2Th cells stably expressing marmoset CD4 and CXCR4, with or without marA3G or
marBST2, were infected withWT (NL4-KBCJ1.2) or Vif SEMQmutant HIV-1. The replication of the viruses is represented as RT activity in the culturemedium
versus time after virus inoculation. The threshold of the RT assay is indicated by the horizontal lines. The infection kinetics of one representative experiment out
of two are shown.
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derivative of the HIV-1 NL4.3 strain containing KB9 Env with the
changes E151K, E172K, and A561T, which allow use of marmoset
CD4 and CXCR4 (30). Throughout this work, we refer to NL4-
KBCJ1.2 as the WT virus. As shown in Fig. 1C, HIV-1 WT and
SEMQ replicated efficiently in the parental cells, which do not
express marA3G or marBST2. However, we did not observe sig-
nificant replication of either virus in cells expressing marA3G or
marBST2, which indicates that marA3G and marBST2 are able to
block HIV-1 replication in cell cultures.
Adaptation ofHIV-1 to commonmarmosetAPOBEC3Gand
BST2. Using a directed-evolution method similar to that em-
ployed in previous virus adaptations (30, 42, 43), we adapted
HIV-1 to replicate in Cf2Th cells expressing marmoset CD4 and
CXCR4 receptors and marA3G or marBST2. The adaptation pro-
tocol is depicted in Fig. 2. We wanted to carry out the adaptation
to marA3G and marBST2 in cells expressing marmoset CD4 and
CXCR4 to ensure that any changes that might appear in the virus
during adaptation would be compatible with the use of these re-
ceptors. The parental Cf2Th cell line used is a dog cell line that was
selected to carry out the adaptation because HIV-1 replicates effi-
ciently in these cells when complemented with an appropriate
CD4 receptor and a CXCR4 or CCR5 coreceptor (42, 44). In ad-
dition, some factors, like A3G or TRIM5, that could potentially
interfere with the adaptations have not been found in the dog
genome (45, 46). The parental HIV-1 strain used for the adapta-
tions was NL4-KBCJ1.2, which can use marmoset CD4 and
CXCR4. In addition to the WT virus, we also studied a mutant
containing the SEMQ changes in Vif, as we had seen that the
mutant was able to partially overcome the block imposed by
marA3G. After several passages of the viruses in cell cultures with
increasing percentages of cells expressing either marA3G or
marBST2, we obtained viruses that were able to replicate in cul-
tures in which 100% of the cells expressed the corresponding re-
striction factor (Fig. 3). Both HIV-1 variants, WT and SEMQ,
adapted to replicate in cells expressing marBST2; however, only
the SEMQ variant adapted to replicate in cell lines expressing
marA3G. These adapted viruseswere passaged a fewmore times in
the marA3G- or marBST2-expressing cell lines to increase viral
fitness (data not shown).
After the adaptation, the genomicDNAof the infected cells was
isolated and the sequences of the integrated HIV-1 proviruses
were amplified and sequenced. We observed changes in several
regions of the viral genome; in the viruses adapted to marA3G,
someG-to-A changes suggestive of the cytidine deaminase activity
of marA3G were observed (Fig. S3 in the supplemental material
shows the LTR region of the viruses passaged in cells expressing
marA3G [Fig. S3A] or marBST2 [Fig. S3B]). We centered our
attention on the changes that appeared in regions that are ex-
pected to be relevant to A3G and BST2 escape—Vif in the case of
marA3G adaptation and Vpu, Env, and Nef in the case of
marBST2 adaptation—and selected those that were maintained
FIG 2 Schematic representation of the direct-evolution strategy. Replication-competent HIV-1 WT or Vif SEMQ mutants were prepared in 293T cells by
transfectionwith the pNL4-KBCJ1.2 plasmid. The viruses produced in the 293T cells were used to infect cell cultures of Cf2Th-marCD4/CXCR4where only 25%
or 30% of the cells expressed marmoset A3G or BST2, respectively. The cell culture supernatants from the day when the RT activity reached a peak were used to
start a new round of infection in a cell culture mixture where 37% or 45% of the cells expressed marmoset A3G or BST2, respectively. The process was repeated
in cell cultures with increasing percentages of cells expressing the restriction factors until we were able to infect cell cultures where all the cells expressed the
restriction factor. After obtaining viruses able to replicate in cell cultures where all the cells expressed marmoset A3G or BST2, the viruses were passaged a few
times in the cell lines.
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during virus passage for further study. Figure 4 shows a schematic
representation of the selected changes in these regions.
The marA3G adaptation gave rise to an initial change in Vif
from Asp99 to Gly. Further passaging of the SEMQ/D99G virus
gave rise to an additional change at residue 71 of Vif (G71D). In
the two adaptations (WT and SEMQ) tomarBST2, changes in Env
and Nef, but not in Vpu, were observed. In addition, we observed
in all three adaptations the appearance of a change in the matrix
protein ofGlu52 to Lys (E52K), whichwas surprising. Two similar
changes in this region of the matrix protein appeared during the
adaptation of NL4-3 and NL4-3(KB9 Env) to replicate in Cf2Th
cells expressing marmoset CD4 and CXCR4 (30).
To study the contributions of these changes to the replication
of HIV-1 in cells expressing marA3G or marBST2, we prepared
viruses containing the changes alone or in certain combinations
and infected target cells.
The adaptation of the WT virus to marBST2 resulted in the
appearance of two single-residue changes, N656S and R742K,
within the sequence of Env that together allowed the replication of
the virus in cells expressing marBST2 (Fig. 5A, right). The Nef
residue change Y202C alone did not permit replication in cells
expressing marBST2, and a combination of this change with the
Env changes did not improve replication efficiency in these cells
(Fig. 5A, right). Although the matrix change E52K alone did not
allow replication of the virus in the presence of marBST2, when
combined with the Env changes, it improved the replication effi-
ciency of the virus (Fig. 5A, right). All these changes in Env, Nef,
andmatrix also increased the replication efficiency in the parental
cell line, which does not express marBST2 (Fig. 5A, left).
In the adaptation of the SEMQvirus tomarBST2, two different
compensatory changes arose in the Env sequence, P722L and
R740K, that allowed low levels of replication in cells expressing
marBST2 (Fig. 5B, right). Viruses containing these Env changes
also had enhanced replication in the parental cell line that does not
express marBST2 compared with the WT virus, and as in the pre-
vious case, addition of the matrix change E52K improved replica-
tion in the presence of marBST2. We did not observe replication
in the cells expressing marBST2 of viruses containing the Nef
changes A15T, C55R, and D150N, which appeared during adap-
tation to marBST2; moreover, a combination of these changes
with the above-mentioned Env changes did not improve replica-
tion in the cells expressing marBST2 (Fig. 5B, right).
The abilities of the different Vif variants to replicate in the
presence of marA3G were studied. The SEMQ mutant had very
low levels of replication in cells expressing marA3G (Fig. 6, top
right). The viruses containing the SEMQ and D99G changes also
initially replicated at low levels in the cells expressing marA3G;
however, after several days in culture, the SEMQ/D99G virus
started to replicate more efficiently, reaching replication levels
close to those attained in the parental cell line (Fig. 6, top). When
all the Vif changes that appeared during adaptation to marA3G
were combined, we also observed low levels of replication in cells
expressingmarA3G (Fig. 6, top right). Although these viruses rep-
licated poorly in cells expressing marA3G, surprisingly, when the
Vif changes were combined with the Env changes N656S and
R742K or P722L and R740K, we obtained viruses that efficiently
replicated in cells expressing marA3G (Fig. 6, middle and bot-
tom). The Env changes in the absence of the Vif changes did not
allow replication in the marA3G cell lines, either alone or com-
bined with the matrix change E52K (Fig. 6, middle and bottom).
Effect ofmarA3G on the infectivity of Vifmutant viruses.To
determine the contributions of the adaptation-associated Vif
changes to the infectivity of the virus, we used a single-cycle infec-
tivity assay. For this purpose, we produced single-cycle viruses
FIG 3 Replication kinetics of the virus at different passages of adaptation. The
charts represent the replication kinetics of the viruses at different steps of the
adaptation process shown in Fig. 2. The RT activity in 0.5 ml of the culture
supernatant wasmeasured at the indicated time points. (A) Adaptation ofWT
virus to marA3G. (B) Adaptation of WT virus to marBST2. (C) Adaptation of
SEMQ virus to marBST2.
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containing WT or mutant Vif proteins and a luciferase reporter
gene in the presence or absence of marA3G. These viruses were
used to infect Cf2Th cells, and the viral infectivity was determined
bymeasuring the relative luciferase activities in the target cells.We
studied the contribution of each mutant individually and in dif-
ferent combinations (Fig. 7A). The SEMQ mutant showed a
2-fold increase in infectivity, as had been observed in our results
shown in Fig. 1A. When all the adaptation-associated changes
were combined with this mutant (SEMQ/G71D/D99G), an addi-
tional increase in infectivity was observed, indicating that the
G71D and D99G changes might also contribute to escape from
marA3G restriction. The other mutants, either G71D or D99G
alone or combined, did not show significant differences in infec-
tivitywith respect toWTviruses. No differences in infectivitywere
observed between WT and Vif viruses, which corroborates the
idea that WT Vif cannot counteract the restriction of marA3G.
Incorporation of marA3G in virions. Vif binds A3G in a spe-
cies-specific way, excluding A3G from incorporating into virions.
To assess the effects of the Vif mutants on the incorporation of
marA3G into virions, we prepared WT or mutant viruses in the
presence of marA3G or huA3G as a control. The viruses were
pelleted, and the amount of A3G incorporated into the viruses was
quantified byWB. The relative amount of A3G incorporated into
virions was calculated as the ratio of A3G (anti-HA antibody) to
p24 in the pelleted viruses (Fig. 7B). As shown in Fig. 7B, the WT
viruses exhibited a significant (about 3-fold) reduction in huA3G
incorporation compared to Vif viruses, in agreement with pre-
viously published results (23–25). With respect to marA3G, the
WT viruses did not show significant differences in A3G incorpo-
ration relative to Vif viruses (Fig. 7B), in agreement with our
previous result showing thatHIV-1Vif cannot overcomemarA3G
restriction (Fig. 7A). The single- and double-residue mutants ex-
hibited only slight variations in A3G incorporationwith respect to
the WT and Vif viruses, while the SEMQ mutant showed an
approximately 2-fold reduction in A3G incorporation relative to
the Vif viruses. The SEMQ/G71D/D99G mutant exhibited the
lowest incorporation of marA3G into nascent viral particles.
These results are consistent with data from the infectivity assays
described above (i.e., viruses that incorporate the smallest amount
of marA3G exhibit the highest infectivity rates) and indicate that
the Vif changes contribute to escape from marA3G restriction by
reducing its encapsidation into virions.
Degradation of marA3G by Vif mutants. After binding to
A3G, Vif targets A3G for proteasomal degradation by recruiting
the E3 ubiquitin ligase complex Cul5-RBX2-ELOB-ELOC (24,
25). We wanted to know whether our Vif mutants were able to
induce degradation of marA3G. For this purpose, we cotrans-
fected 293T cells with a vector expressing WT or mutant Vif and
marA3G (or, as a control, huA3G, agmA3G, or rhA3G) and mea-
sured the steady-state levels of A3G by WB. Supporting our pre-
vious results, we observed that coexpression with Vif proteins
containing the SEMQ or SEMQ plus G71D and D99G changes
FIG 4 Schematic representation of the HIV-1 genome and the encoded Vif, Env, and Nef proteins showing domains and relevant changes that arose during
adaptation. The horizontal line with tick marks represents the full genome of the virus. Each tick corresponds to 1,000 nucleotides. The genomes of the adapted
viruses were amplified by PCR from genomic DNA isolated from the infected cells. The PCR fragments were either directly sequenced or cloned in a vector and
then sequenced. The changes that appeared in regions that were expected to be relevant to A3G or BST2 escape (Vif, Env, and Nef) and that were maintained in
successive passages are shown as vertical bars. V1 to V5, variable regions; FP, fusion peptide; HR1/2, helical regions 1 and 2; TM, transmembrane domain; CT,
cytoplasmic tail.
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resulted in lower levels of marA3G in the cells than with WT Vif
(Fig. 7C). The addition of a proteasome inhibitor, MG132, re-
duced the ability of theVifmutants to degrademarA3G compared
with WT Vif, suggesting that, as previously reported for huA3G
(25), these Vif variants induce degradation of marA3G though a
proteasome-mediated pathway (Fig. 7C, bottom).
As expected,WTVif was able to reduce the expression levels of
huA3G, but not agmA3G or rhA3G, while the SEMQmutant had
a reduced ability to induce degradation of huA3G and an in-
creased ability to induce degradation of agmA3G, in agreement
with the respective loss and gain of anti-huA3G and anti-agmA3G
activity of the mutant (41).
Effect ofmarBST2 in particle release of Envmutants.BST2 is
a type II transmembrane protein that also has a C-terminal glyco-
sylphosphatidylinositol (GPI) anchor, allowing it to interact with
lipid membranes at both ends. Thanks to this unusual topology,
BST2 prevents the release of mature virions by keeping them an-
chored to the cell surface. The HIV-1 Vpu accessory protein an-
tagonizes the effect of human BST2 and restores normal virus
budding and release during infection. To establish if the Env
changes in the viruses adapted tomarBST2-expressing cells exert a
similar effect, we carried out a particle release assay. Viruses con-
taining the Envmutantswere produced in 293T cells in the presence
or absence ofmarBST2. The amount of p24 in the intracellular (pro-
cessing andanchoredviruses) andextracellular (released free virions)
fractionswas determined by immunoblottingwith a polyclonal anti-
bodyelicitedagainstp24; thepercentageof releasedviral particleswas
calculated as the ratio of p24 in the virions (extracellular) to the total
p24 (intracellular plus extracellular) (Fig. 8A). Even though we had
seen that the N656S/R742K and P722L/R740K Env mutants were
able to replicate in cells that expressmarBST2 (Fig. 5),whenwe tested
theeffectsof theEnvmutationsonparticle release,wedidnotobserve
significant differences in particle release with respect to WT viruses
(Fig. 8A) or the controlVpu viruses (Fig. 1B).
FIG 5 Replication kinetics of HIV-1 mutants derived from adaptation to marmoset BST2. Cf2Th cells expressing marmoset CD4 and CXCR4, with (right) or
without (left) marBST2, were infected with different HIV-1 variants. The RT activity in 0.5 ml of the culture supernatant was measured at the indicated time
points. (A) Replication of viruses containing the Env changes that appeared during the adaptation of the WT virus to marBST2. (B) Replication of viruses
containing the Env changes that appeared during the adaptation of the SEMQ virus to marBST2. The replication of the WT virus is shown in all the charts as a
reference. The threshold of the RT assay is indicated by the horizontal lines. The results of one infection experiment out of two are shown.
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Effect ofEnvmutantson the internalizationanddegradation
of BST2. The interaction between HIV-1 Vpu and huBST2 leads
to the endocytosis of BST2, endosome sequestration, and partial
proteasome degradation of BST2 (47–54). The ability of the Env
mutants to downregulate/degrade BST2 was studied by WB and
flow cytometry.
First, we studied the effect of the expression of WT or mutant
Env on the steady-state expression levels of BST2 in 293T cells by
WB. While we had observed that the addition of Vpu decreased
the expression levels of huBST2 (Fig. 1B), we did not observe a
reduction in the expression levels of marBST2 either in the pres-
ence of the different Env variants (Fig. 8B) or in the presence of
HIV-1 Vpu or SIVmac Nef (Fig. 1B).
One possibility is that the Envmutants decrease the amount of
BST2 on the cell surface, inducing the internalization of the pro-
tein without an effect on the total levels of protein expression, as
FIG 6 Replication kinetics of HIV-1 mutants derived from adaptation to marmoset A3G. Cf2Th cells expressing marmoset CD4 and CXCR4, with (right) or
without (left) marA3G, were infected with different HIV-1 variants. The RT activity in 0.5 ml of the culture supernatant was measured at the indicated time
points. The replication of the WT virus is shown in all the charts as a reference. The threshold of the RT assay is indicated by the horizontal lines. The results of
one infection experiment out of two are shown.
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FIG 7 Adaptation-induced changes in Vif increase viral infectivity in the presence of marA3G and reduce the packaging of marA3G into virions and the total
expression level of marA3G. (A) Effects of marA3G on the infectivity of Vif mutant viruses. Luciferase reporter viruses pseudotyped with VSV-G and containing
WTormutant Vif proteins were produced in 293T cells in the presence or absence ofmarA3G. The viruses were used to infect Cf2Th target cells, and 2 days later,
the infectivity of the viruses was determined bymeasuring the relative luciferase activities in the target cells. The relative infectivity of each variant was calculated
by dividing the infectivity of the viruses prepared in cells expressingmarA3G by the infectivity of the viruses prepared in cells that did not express A3G. Themean
relative infectivities  standard deviations of four independent experiments (with each point tested in duplicate) are represented. Two-tailed P values were
calculated using Student’s t test. (B) Incorporation of marA3G into virions. WT or mutant Vif viruses were produced in 293T cells in the presence or absence of
marA3G. The viruses were pelleted by centrifugation in a 20% sucrose cushion and analyzed by immunoblot probing with an anti-HA antibody (A3GHA) and an
anti-p24 antibody. A representativeWB out of 5 independent experiments is shown. The relative amount of A3G incorporated into virions was calculated as the
ratio of HA (A3G) to p24 and normalized to 1, relative toVif. The averages of the relative A3G incorporated for the five experiments standard deviations are
shown above the WB. (C) A3G degradation by Vif mutants. 293T cells were cotransfected with a vector expressing marA3G, huA3G, agmA3G, or rhA3G
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has been reported for HIV-2 Env (12). Using two different anti-
bodies raised against huBST2, we studied the cell surface expres-
sion levels of marBST2 in the presence of WT or mutant Env.
However, the antibodies used were raised against huBST2 and
exhibited only very low affinity formarBST2; using this approach,
we did not observe a significant difference in surface expression
levels of marBST2 in the presence or absence of Env variants or
Vpu (data not shown). Using a marBST2 with an internal HA tag
(which should be exposed on the cell surface), we did not observe
differences in cell surface expression levels of the protein in the
presence or absence of theWTor Envmutants. However, the total
expression levels of the construct were much lower than the
expression levels of marBST2 with an N-terminal tag, which
had been used in all the other experiments. Furthermore, this
marBST2 with an internal HA tag was unable to block the re-
lease of HIV-1. Although these results are not fully conclusive
due to the lack of an anti-BST2 antibody that efficiently recog-
nizes marBST2, the Env mutants do not appear to downregu-
late marBST2 from the cell surface.
Infectivity of the Env mutant viruses. The adaptations of
HIV-1 to marBST2 led to the appearance of a few changes in Env
that allow viral replication in cells that express this restriction
factor. These changes also increase replication efficiency in the
parental cell lines that do not express marBST2 (Fig. 5). However,
our data indicated that the Env mutants did not increase the effi-
ciency of particle release or induce the degradation/internaliza-
tion of marBST2. We decided to study the infectivity of Env mu-
tant viruses using single-cycle luciferase reporter viruses. Higher
infectivity of the Env mutants relative to WT viruses could indi-
cate that HIV-1 had adapted to overcome marBST2 by introduc-
ing changes that improve viral fusion and entry into the host cell;
in this way, the Env mutants might compensate for the effect of
marBST2 instead of adapting the envelope proteins to directly
counteract marBST2 with a Vpu-like activity.
Single-round viruses containing the WT or mutant Env and a
luciferase reporter genewere produced in the absence ofmarBST2
andwere used to infect Cf2Th cells expressingmarmoset CD4 and
CXCR4 receptors. Viruses used to infect target cells were isolated
from donor cells, so this systemmeasures cell-free viral infectivity
(Fig. 9A). Viral infectivity was determined by measuring the rela-
tive luciferase activity in the target cells 48 h postinfection (Fig.
9B). In this assay, Envmutants exhibited infectivity similar to that
ofWT viruses. These results argue against a direct effect of the Env
changes on viral entry per se.
Cell-to-cell transmission of Env mutants. HIV and many
other viruses are transmitted not only as cell-free viral particles
diffusing in the extracellular environment, but also directly and
more efficiently by cell-to-cell transfer through virological syn-
apses formed between the infected cell and a target cell (55, 56).
Since we did not observe an improvement in cell-free infectiv-
ity between WT and mutant Env viruses, we wanted to deter-
mine if Env mutants could overcome the marBST2 restriction
by favoring cell-to-cell transmission. For this purpose, HIV-1
pseudoviral particles containing WT or Env mutants, as well as
the GFP reporter gene, were produced in 293T cells (donor
cells). Twenty-four hours posttransfection, 174CEM cells
previously labeled with DDAO-SE (target cells) were added
and cocultured for 2 days. Viral transmission was assessed by
flow cytometry measuring the percentage of GFP- and DDAO-
SE-double-positive cells. We focused on target cells that had
been infected, which should be DDAO GFP double-positive
cells, and we compared the percentages of target cells infected
in the presence and absence of marBST2 to calculate the rela-
tive viral transmission (Fig. 9C). The presence of marBST2
containing a C-terminal HA tag and a plasmid expressing a partially codon-optimized Vif with different changes. Twenty-four hours later, the cells were
harvested and lysed. The cell lysates were analyzed byWBwith an anti-HA antibody, and the amount of A3G was quantified. The membranes were stripped and
reprobed with an anti-Vif antibody; then, the membranes were stripped again and probed with an anti-tubulin antibody as a loading control. A representative
WB out of two independent experiments is shown. The relative amount of A3G in the cells was calculated as the ratio of HA (A3G) to tubulin and normalized
to 1 relative to WT Vif. The averages of the relative A3G in the cells for the two experiments standard deviations are shown above the WB.
FIG 8 No differences in particle release and in total expression of marBST2 were observed in the presence of Env mutants. (A) Particle release of Env mutant
viruses in the presence of marBST2. Viruses containing WT or mutant Env were produced in 293T cells in the presence or absence of marBST2 or huBST2.
Twenty-four hours later, the medium was collected and the viruses were pelleted by centrifugation in a 20% sucrose cushion. The cell lysates and viruses were
analyzed by immunoblot probingwith an anti-p24 antibody. The percentage of particle release was calculated as the ratio of p24 in the released virions to the total
p24 (virions plus cell lysates). (B) Total expression of marBST2. The same experiments shown in panel A were performed. The membranes were stripped and
reprobed with an anti-HA antibody (to detect BST2HA); then, themembranes were stripped again and probed with an anti-tubulin antibody as a loading control
(bottom). The experiments were repeated 3 times with similar results. The WBs of one representative experiment are shown.
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greatly reduced viral transmission of WT viruses compared to
the viral transmission in the absence of the restriction factor.
The Env mutants improved viral transmission in the presence
of marBST2 at different levels. The compensatory changes
N656S/R742K were associated with the highest viral transmis-
sion ratio. As expected, the control infection adding NVP, a
potent inhibitor of reverse transcriptase, drastically reduced
viral transmission in both the presence and absence of
marBST2. These results suggest that the N656S/R742K and
P722L/R740K Env mutants escape marBST2 al least in part by
increasing cell-to-cell viral transmission. Together, our results
suggest that the mechanism that the virus uses to escape
marBST2 might be different from that reported previously for
HIV-1 Vpu and huBST2 (3, 4).
DISCUSSION
Here, we have studied the blockade of HIV-1 by common mar-
moset A3G and BST2 and adapted HIV-1 to replicate in the pres-
ence of these restriction factors. We also started to explore the
escape mechanisms that HIV-1 develops to evade marA3G and
marBST2 in cell cultures. Just a few mutations that emerged dur-
ing the adaptation within the Vif and Env sequences of HIV-1
were sufficient to partially overcome marA3G and marBST2 and
to allow replication of these viruses in cell lines that express the
restriction factors.
The analysis of mutants adapted to replicate in the presence of
marA3G revealed that two single changes within the sequence of
HIV-1 Vif, in addition to the SEMQ changes, appeared to partially
FIG 9 Adapted HIV-1 Env variants do not show differences in cell-free infectivity but increase cell-to-cell transmission. (A) Schematic representation of the
cell-free viral-infectivity and cell-to-cell transmission assays. FACS, fluorescence-activated cell sorting. (B) Cell-free virus infectivity assay. Luciferase reporter
viruses expressingWT or mutant Env were produced in 293T cells in the absence of marBST2. After 48 h, viruses were harvested and isolated. Serial dilutions of
each virus were used to infect Cf2Th cells expressing marmoset CD4 and CXCR4 receptors. Two days later, the infectivity of the viruses was determined by
measuring the relative luciferase activity in the target cells. Similar results were obtained in two independent experiments. The results of one representative
experiment are shown. (C) Cell-to-cell transmission assay. 293T donor cells were transfected with constructs for expression of HIV-1 GFP reporter viruses
containingWT ormutant Env in the presence or absence of marBST2. Twenty-four hours later, the cells were mixed with 174CEM target cells prelabeled with
DDAO-SE and cocultured. (Left) Two days later, the target cells were analyzed by flow cytometry for DDAO andGFP expression, and the percentage of DDAO
GFP double-positive cells (infected target cells) was determined. (Right) The relative viral transmission was calculated as the ratio of infected target cells in the
presence of marBST2 to infected target cells in the absence of marBST2. The results shown in the charts represent the means  standard deviations of four
independent experiments, each done in duplicate. Two-tailed P values were calculated using Student’s t test.
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overcome the marA3G block. Previous studies have shown that sev-
eral residues in the N terminus of Vif are part of a nonlinear binding
site for humanA3G andA3F (Fig. 4) (37–40). Furthermore, residues
14 to17(DRMR),whicharenecessary for interactionwithhuA3Fbut
not critical for Vif binding to huA3G, have also been observed to
facilitate species-specific recognition of A3G (40, 41). All our ob-
served changes, SEMQ, G71D, and D99G, are located within the Vif
N-terminal region. Moreover, these residues seem to be well con-
served in a species-specific manner; thus, a priori, one might expect
that they have emerged to allow HIV-1 Vif protein to specifically
recognize marA3G, a model that our experimental results seem to
corroborate. Previous studies had already demonstrated that the in-
teractionbetweenVif andA3Gishighly species specific; evena single-
amino-acid change could modify the specificity of Vif. For example,
theD128K substitution in humanA3Gprevents the interactionwith
HIV-1 Vif but allows the interaction with SIVagm Vif (57).
The set of changes that emerged at the end of the adaptation
(SEMQ/G71D/D99G) partially counteracts marA3G by reducing
the incorporation ofmarA3G into nascent virionsmore efficiently
than the singlemutations (Fig. 7B). This reduced incorporation of
marA3G into virions seems to be due to a decrease in the steady-
state levels of marA3G in the presence of these Vif mutants. A3G
incorporation into virions, as well as the ability ofHIV and SIVVif
proteins to block its packaging, has been previously studied (23,
58). HIV-1 Vif has been successfully modified to overcome the
A3G restriction factor of rhesus macaques and African green
monkeys (41). In each case, there was a direct correlation between
the decrease of A3G packaging into virions and the increase in the
infectivity of these virions, which is consistent with the results
obtained in our study.We hypothesize that ourVifmutantsmain-
tain the same escape mechanism that HIV-1 uses to counteract
huA3G but have adapted their structures to favor the interaction
with marA3G.
In the case of HIV-1 adaptation to replicate in the presence of
marBST2, the analysis of mutants revealed that compensatory
changes emerged within the sequence of the envelope glycopro-
teins instead of appearing in Vpu, which is the protein evolved by
HIV-1 to counteract human BST2 in nature. In each adaptation,
two Env changes, N656S/R742K or P722L/R740K, were shown to
be sufficient to overcome the marBST2 block in cell cultures.
Vpu is one of the accessory proteins of HIV-1, although it is
absent in other, related primate lentiviruses, such as HIV-2 and
most SIVs. In these viruses, the block imposed by BST2 is coun-
teracted by the envelope glycoproteins of HIV-2 and the Nef pro-
tein of SIVs (12–16). The ability to counteract BST2 by adapting
different viral proteins suggests that overcoming the restriction of
BST2 is a key factor for improving viral pathogenesis. Antagonism
of BST2 by HIV-1 Env has not been previously described. How-
ever, a previous study found that compensatory changes in the
cytoplasmic tail of gp41 restored resistance to BST2 in a strain of
SIV with nef deleted, which regained a pathogenic phenotype in
rhesus macaques (59). These studies suggest that when Nef is not
an alternative as a BST2 antagonist, Env can evolve to counteract
its effects. Some of the Nef changes that arose in our adaptation
increased the replication efficiency of the virus in the parental cell
lines; however, they were not able to counteract marBST2 (Fig. 5).
A recent publication has shown that canine BST2 (dogBST2) is
able to blockHIV-1 particle release (60). HIV-1 is able to replicate
efficiently in Cf2Th cells if they are engineered to express a func-
tional CD4 andCXCR4orCCR5.However, the titer of the virus in
these cell lines is not as high as in human cell lines. Thus, it is
possible that an endogenous dogBST2 expressed in theCf2Th cells
exerts mild activity against HIV-1 and that someNef changes, like
Y202C, counteract dogBST2. During the adaptation of SEMQ to
marBST2, some changes in Nef also evolved (data not shown).
Although their contributions to viral replication were not tested,
this supports the idea that dogBST2 expressed in Cf2Th cells
might have some mild activity against HIV-1. If Nef is used to
counteract dogBST2, then Env would be a reasonable alternative
for marBST2 counteraction.
In contrast to many previous studies that showed that over-
coming BST2 restriction results in an increase in the amount of
released virions, we observed no differences in particle release in-
duced by Env mutants. Furthermore, no differences in the total
marBST2 expression levels or signals of degradation induced by
Env mutants were observed. These results together suggest that
adapted Envmutants do not use the samemolecular escapemech-
anism as Vpu, which mediates ubiquitination and proteasomal
degradation of BST2 (49). Since BST2 is a membrane protein,
HIV-1 variants adapted to marBST2 could operate by removing
marBST2 from the plasma membrane without affecting the total
amount of BST2; such a situation occurs with HIV-2 Env, whose
escape mechanism consists of endosomal sequestration of BST2
within the trans-Golgi network, with no concomitant BST2 degra-
dation (12). However, our preliminary results studying marBST2
downregulation from the plasmamembrane by flow cytometry in-
dicate that the Env mutants do not decrease the total amount of
marBST2 at the plasma membrane.
HIV-1 Env variants adapted to replicate in the presence of
marBST2 do not show significant differences in cell-free viral in-
fectivity but moderately increase cell-to-cell transmission. BST2
has been observed to restrict both cell-free and direct cell-to-cell
transmission (61–63). Cell-free transmission involves the release
of viruses in the extracellular medium and their free diffusion
until they reach a new host cell, which means that virions spend
more time in the extracellular medium. One possible explanation
for not observing differences in cell-free viral infectivity between
WT andmutant viruses is that HIV-1 Envmutants could bemore
unstable than the WT Env, becoming inactivated more rapidly
under the conditions used in the cell-free viral-infectivity assay.
However, cell-to-cell transmission allows more rapid and direct
transfer of the virus through virological synapses. Our results in-
dicate that Envmutants can overcome the marBST2 restriction in
part by increasing cell-to-cell transmission, although the exact
mechanism is still not clear and does not seem to directly target
marBST2. In a recent study, Durham and Chen (64) have shown
that HIV-1 cell-free and cell-to-cell infections are differentially
regulated by distinct elements in the cytoplasmic tail of gp41. They
propose that during cell-to-cell infection there are differences in
the function of Env during virological synapse formation com-
pared to cell-free infection and that the formation of the virolog-
ical synapse can overcomepackaging or other defects. It is possible
that our Envmutants compensate for the defect in particle release
imposed by marBST2, at least in part, through a mechanism that
favors virological synapse formation.
The Env changes that allow replication in cells that express
marBST2 also increase the replication infectivity of the virus in the
parental cells that do not express marBST2 (Fig. 5 and 6). Al-
though these envelope changes do not allow efficient replication
in cells that expressmarA3G,when combinedwith theVif changes
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that allow partial escape from marA3G, they increase viral repli-
cation in the marA3G-expressing cells (Fig. 6). These results to-
gether indicate that escape from these restriction factors is linked
to an increase in viral fitness, at least in the Cf2Th cell lines. Pre-
vious studies have shown that an increase in the viral fitness of
hepatitis C virus passaged in tissue culture cells is associated with
increased resistance to inhibitors of viral replication that target
viral or cellular factors without the appearance of mutations spe-
cifically associated with resistance to the inhibitors (65). In our
case, we found that adaptation to restriction factors is associated
with the appearance of mutations that also increase viral fitness
and that the increase in fitness allows replication in the presence of
the restriction factors. In the case of marBST2, it appears that an
increase in viral fitness is sufficient to allow escape from the block-
ade; in contrast, in the case of A3G, the combination of some
changes in Vif that partially overcome the marA3G block plus
some changes that increase viral fitness is needed. The main dif-
ference between the situations might be related, on one hand, to
the different strengths of marBST2 and marA3G restriction and,
on the other hand, to the different mechanisms of action of the
restriction factors. Our results show that the blockade imposed by
marBST2 is not as strong as the blockade imposed by huBST2 (Fig.
1B). This situation might favor a mechanism of escape that in-
volves an increase in viral fitness in the target cells.We believe that
the blockade imposed by marA3G is stronger, and thus, some
A3G-specific Vif changes are needed to overcome the block.
In summary, we have identified compensatory genetic changes
that provide resistance to common marmoset APOBEC3G and
BST2 in HIV-1 strains adapted to infect cells expressing these
restriction factors, with the ultimate goal of developing a new
animal model for AIDS research involving infection with more
complete HIV-1-like viruses. Preliminary studies combining the
Env and Vif changes shown in this work with changes that allow
use of marmoset CD4 and CXCR4 (30) did not allow replication
of the virus in marmoset PBLs (data not shown). One reasonable
explanation for this lack of replication in marmoset PBLs is that
the viruses have evolved to overcomemarmoset A3G and BST2 in
the context of canine cells. It is also possible that in marmoset
PBLs different or additional changes may be needed to efficiently
overcome A3G and BST2. However, we have obtained evidence
for the existence of at least two early postentry blocks to HIV-1
that are not mediated by TRIM5 in marmoset lymphocytes (B.
Pacheco, L. Menéndez-Arias, and J. Sodroski, unpublished data
and data presented at the 40th Meeting on Retroviruses, Cold
Spring Harbor, NY, 18 to 23 May 2015). These early postentry
blocks are strong enough to prevent replication of the viruses in
the marmoset lymphocytes, even if the viruses were perfectly
adapted to marmoset A3G and BST2. Currently, we are investi-
gating the nature of the factors involved in these early postentry
blocks and adapting HIV-1 to overcome them. The Env and Vif
mutants obtained in this work are a good starting point for further
adaptation in marmoset PBLs.
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